Hospital
Moundview Memorial Hospital & Clinics, INC
Moundview Memorial Hospital & Clinics, INC was paid $8.85M by Medicaid between Jan 2018 and Dec 2024, across 112 billing codes. Its largest line is 99283, emergency room visit (moderate) — 28% of everything it billed.
33Billing provider infoMOUNDVIEW MEMORIAL HOSPITAL & CLINICS, INC
FRIENDSHIP, WI 53934
FRIENDSHIP, WI 53934
33aNPI1710939533assigned 05/17/2006
33bProvider typeCritical Access Hospital
28Total paid$8.85M
24GClaims115,145
24DCodes billed112
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Wisconsin
Rank by total paid#13 of 48
Median peer was paid$4.30M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,178 | $812K | |
| 2019 | 17,151 | $1.01M | |
| 2020 | 16,576 | $883K | |
| 2021 | 18,178 | $1.22M | |
| 2022 | 15,463 | $1.64M | |
| 2023 | 16,510 | $1.75M | |
| 2024incomplete | 16,089 | $1.53M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 11,498 | 9,717 | $2.48M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 6,437 | 5,026 | $1.61M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 16% | 5,459 | 4,777 | $1.40M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.1% | 2,854 | 2,202 | $719K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.3% | 3,376 | 2,970 | $643K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.2% | 834 | 691 | $371K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.8% | 1,843 | 1,679 | $250K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.6% | 4,277 | 1,700 | $139K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.2% | 3,829 | 1,693 | $110K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.0% | 591 | 532 | $90K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,358 | 2,167 | $86K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 393 | 345 | $82K |
100 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 939 | $72K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 169 | $64K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 715 | $60K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,668 | $53K |
| 80053 | Comprehensive metabolic panel | <1% | 4,926 | $41K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 236 | $39K |
| 80050 | General health panel | <1% | 1,618 | $35K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 766 | $31K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,353 | $31K |
| 80061 | Lipid panel | <1% | 2,280 | $29K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 604 | $28K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 25 | $27K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,057 | $26K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,288 | $25K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 642 | $22K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,836 | $19K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 380 | $16K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,038 | $16K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 34 | $15K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,205 | $15K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 626 | $14K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,220 | $12K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 473 | $12K |
| 84484 | <1% | 1,947 | $10K | |
| 85610 | <1% | 1,232 | $10K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,755 | $9K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 26 | $8K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,249 | $8K |
| 80051 | <1% | 1,122 | $7K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,473 | $7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 515 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 733 | $7K |
| 82565 | <1% | 1,538 | $7K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 13 | $6K |
| 83690 | <1% | 1,318 | $6K | |
| 83735 | <1% | 1,318 | $6K | |
| 97162 | <1% | 137 | $6K | |
| 81001 | <1% | 1,687 | $5K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 32 | $4K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 114 | $4K |
| 94761 | <1% | 2,020 | $4K | |
| 87081 | <1% | 434 | $4K | |
| 82607 | <1% | 244 | $3K | |
| 81025 | <1% | 413 | $3K | |
| 83880 | <1% | 261 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,686 | $3K |
| 87077 | <1% | 375 | $3K | |
| 82077 | <1% | 262 | $2K | |
| 80306 | <1% | 169 | $2K | |
| 82947 | <1% | 758 | $2K | |
| 87186 | <1% | 313 | $2K | |
| 84460 | <1% | 466 | $2K | |
| 81003 | <1% | 895 | $2K | |
| 85027 | <1% | 389 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,479 | $2K |
| 82043 | <1% | 157 | $1K | |
| 84520 | <1% | 512 | $1K | |
| 83605 | <1% | 311 | $1K | |
| 80305 | <1% | 90 | $1K | |
| 73630 | <1% | 28 | $1K | |
| 82728 | <1% | 84 | $1K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 67 | $939.98 |
| 73030 | <1% | 16 | $752.78 | |
| 90688 | <1% | 23 | $632.75 | |
| 87040 | <1% | 129 | $546.04 | |
| 84439 | <1% | 56 | $481.04 | |
| 82746 | <1% | 31 | $462.50 | |
| Q3014 | Telehealth originating site facility fee | <1% | 23 | $389.44 |
| 87420 | <1% | 21 | $386.77 | |
| 83540 | <1% | 61 | $372.61 | |
| 86140 | <1% | 85 | $361.87 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 13 | $359.10 |
| 82962 | <1% | 148 | $352.24 | |
| 85007 | <1% | 133 | $251.46 | |
| 82150 | <1% | 47 | $240.02 | |
| 84466 | <1% | 14 | $212.16 | |
| 85379 | <1% | 40 | $210.40 | |
| 83550 | <1% | 29 | $202.68 | |
| 84481 | <1% | 13 | $166.20 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 55 | $141.79 |
| 84075 | <1% | 32 | $131.70 | |
| 85730 | <1% | 24 | $108.18 | |
| 73610 | <1% | 14 | $102.61 | |
| 82550 | <1% | 15 | $85.56 | |
| 85652 | <1% | 34 | $85.26 | |
| 82553 | <1% | 14 | $71.15 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16 | $70.90 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,840 | $39.21 |
| 82247 | <1% | 16 | $38.16 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 826 | $33.29 |
| 74019 | <1% | 13 | $33.19 | |
| 36592 | <1% | 184 | $33.11 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 831 | $30.88 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,622 | $19.52 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 95 | $14.31 |
| A9270 | Non-covered item or service | <1% | 2,836 | $8.61 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 222 | $0.54 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 58 | $0.00 |
| J3490 | Unclassified drugs | 0% | 31 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPEREZ-GUERRA, FRANK (CEO)
Parent organizationMOUNDVIEW MEMORIAL HOSPITAL & CLINICS INC
| Provider | Location | Paid |
|---|---|---|
| Moundview Memorial Hospital & Clinics, INC. | Friendship, WI | $388K |
| Moundview Memorial Hospital & Clinics, INC. | Westfield, WI | $6K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.